{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:18:39Z","timestamp":1792214319466,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00277-021-04603-y","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T03:02:52Z","timestamp":1626663772000},"page":"2513-2519","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Outcomes of Richter\u2019s transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): an analysis of the SEER database"],"prefix":"10.1007","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6159-3768","authenticated-orcid":false,"given":"Radowan","family":"Elnair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moataz","family":"Ellithi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avyakta","family":"Kallam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Shostrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Bociek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,19]]},"reference":[{"issue":"6","key":"4603_CR1","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/bjh.12458","volume":"162","author":"SA Parikh","year":"2013","unstructured":"Parikh SA et al (2013) Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol 162(6):774\u2013782","journal-title":"Br J Haematol"},{"key":"4603_CR2","unstructured":"Richter MN (1928) Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia. Am J Pathol 4(4): 285\u2013292.7"},{"issue":"15","key":"4603_CR3","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","volume":"24","author":"AM Tsimberidou","year":"2006","unstructured":"Tsimberidou AM et al (2006) Clinical outcomes and prognostic factors in patients with Richter\u2019s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 24(15):2343\u20132351","journal-title":"J Clin Oncol"},{"issue":"6","key":"4603_CR4","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1080\/10428194.2020.1719092","volume":"61","author":"Y Ben-Dali","year":"2020","unstructured":"Ben-Dali Y et al (2020) Richter\u2019s transformation in patients with chronic lymphocytic leukaemia: a nationwide epidemiological study. Leuk Lymphoma 61(6):1435\u20131444","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"4603_CR5","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1097\/PAS.0b013e31804bdaf8","volume":"31","author":"Z Mao","year":"2007","unstructured":"Mao Z et al (2007) IgVH mutational status and clonality analysis of Richter\u2019s transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol 31(10):1605\u20131614","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"4603_CR6","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","volume":"117","author":"D Rossi","year":"2011","unstructured":"Rossi D et al (2011) The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 117(12):3391\u20133401","journal-title":"Blood"},{"issue":"12","key":"4603_CR7","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1002\/cncr.30596","volume":"123","author":"P Jain","year":"2017","unstructured":"Jain P et al (2017) Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer 123(12):2268\u20132273","journal-title":"Cancer"},{"key":"4603_CR8","doi-asserted-by":"crossref","unstructured":"Davids MS, et al (2017) Richter\u2019s syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy. J Clin Oncol 35(15_suppl):7505\u20137505","DOI":"10.1200\/JCO.2017.35.15_suppl.7505"},{"issue":"25","key":"4603_CR9","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","volume":"129","author":"MA Anderson","year":"2017","unstructured":"Anderson MA et al (2017) Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood 129(25):3362\u20133370","journal-title":"Blood"},{"issue":"19","key":"4603_CR10","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1182\/bloodadvances.2017007302","volume":"1","author":"CR Miller","year":"2017","unstructured":"Miller CR et al (2017) Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. Blood Adv 1(19):1584\u20131588","journal-title":"Blood Adv"},{"key":"4603_CR11","doi-asserted-by":"crossref","unstructured":"Al-Sawaf O et al (2021). Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia,\u00a035(1), 169\u2013176.","DOI":"10.1038\/s41375-020-0797-x"},{"key":"4603_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1186\/1471-2407-10-625","volume":"10","author":"R Griffiths","year":"2010","unstructured":"Griffiths R et al (2010) Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL). BMC Cancer 10:625\u2013625","journal-title":"BMC Cancer"},{"issue":"11","key":"4603_CR13","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1002\/cncr.25765","volume":"117","author":"PJ Shenoy","year":"2011","unstructured":"Shenoy PJ et al (2011) Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer 117(11):2530\u20132540","journal-title":"Cancer"},{"key":"4603_CR14","doi-asserted-by":"crossref","unstructured":"Abrisqueta P et al (2020). Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC). British journal of haematology, 190(6), 854\u2013863.\u00a0","DOI":"10.1111\/bjh.16748"},{"issue":"6","key":"4603_CR15","first-page":"1294","volume":"107","author":"AM Tsimberidou","year":"2006","unstructured":"Tsimberidou AM et al (2006) Hodgkin transformation of chronic lymphocytic leukemia: the M. D Anderson Cancer Center experience. Cancer 107(6):1294\u20131302","journal-title":"D Anderson Cancer Center experience Cancer"},{"key":"4603_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.humpath.2016.04.019","volume":"55","author":"W Xiao","year":"2016","unstructured":"Xiao W et al (2016) Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion. Hum Pathol 55:108\u2013116","journal-title":"Hum Pathol"},{"issue":"12","key":"4603_CR17","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.bbmt.2016.09.013","volume":"22","author":"MA Kharfan-Dabaja","year":"2016","unstructured":"Kharfan-Dabaja MA et al (2016) Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 22(12):2117\u20132125","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"4603_CR18","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1200\/JCO.2011.37.4108","volume":"30","author":"K Cwynarski","year":"2012","unstructured":"Cwynarski K et al (2012) Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter\u2019s syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 30(18):2211\u20132217","journal-title":"J Clin Oncol"},{"issue":"1","key":"4603_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","volume":"1","author":"KJ Maddocks","year":"2015","unstructured":"Maddocks KJ et al (2015) Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol 1(1):80\u201387","journal-title":"JAMA Oncol"},{"issue":"18","key":"4603_CR20","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1182\/bloodadvances.2020002454","volume":"4","author":"PJ Hampel","year":"2020","unstructured":"Hampel PJ et al (2020) Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. Blood Adv 4(18):4508\u20134511","journal-title":"Blood Adv"},{"issue":"25","key":"4603_CR21","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1182\/blood-2018-01-791376","volume":"131","author":"D Rossi","year":"2018","unstructured":"Rossi D, Spina V, Gaidano G (2018) Biology and treatment of Richter syndrome. Blood 131(25):2761\u20132772","journal-title":"Blood"},{"issue":"10254","key":"4603_CR22","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254):839\u2013852","journal-title":"Lancet"},{"issue":"1","key":"4603_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45\u201356","journal-title":"N Engl J Med"},{"issue":"26","key":"4603_CR24","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531\u20132544","journal-title":"N Engl J Med"},{"issue":"19","key":"4603_CR25","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.1182\/bloodadvances.2020002783","volume":"4","author":"AS Kittai","year":"2020","unstructured":"Kittai AS et al (2020) Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome. Blood Adv 4(19):4648\u20134652","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"4603_CR26","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2018-99-120355","volume":"132","author":"N Jain","year":"2018","unstructured":"Jain N et al (2018) A phase II trial of nivolumab combined with ibrutinib for patients with Richter transformation. Blood 132(Supplement 1):296\u2013296","journal-title":"Blood"},{"key":"4603_CR27","doi-asserted-by":"crossref","unstructured":"Davids MS, et al (2020) A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter\u2019s syndrome. J Clin Oncol 38(15_suppl):8004\u20138004","DOI":"10.1200\/JCO.2020.38.15_suppl.8004"},{"issue":"S2","key":"4603_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/hon.79_2629","volume":"37","author":"AR Mato","year":"2019","unstructured":"Mato AR et al (2019) Phase I\/II study of umbralisib (TGR-1202) in combination with ublituximab (TG-1101) and pembrolizumab in patients with Rel\/Ref Cll and Richter\u2019s transformation. Hematol Oncol 37(S2):119\u2013120","journal-title":"Hematol Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04603-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04603-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04603-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T04:11:36Z","timestamp":1631592696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04603-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,19]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["4603"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04603-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,19]]},"assertion":[{"value":"2 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study utilized a widely available database. Individual patient consent was thus not obtained for the purpose of this study. All data were collected and used following the SEER policies and procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}